Welcome!

Microsoft Cloud Authors: David H Deans, Yeshim Deniz, Janakiram MSV, Andreas Grabner, Stackify Blog

News Feed Item

Vermillion Reports Third Quarter 2012 Results

AUSTIN, Texas, Nov. 12, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, reported financial and operational results for the third quarter ended September 30, 2012.

Q3 2012 Operational Highlights

  • In Q3, the volume of OVA1®, the company's flagship diagnostic test designed to help differentiate benign from malignant ovarian masses, was in line with management's forecast at approximately 4,100 tests.
  • Submitted a manuscript on the OVA500 pivotal study by principal investigator, Dr. Robert Bristow of UC Irvine. This second prospective study of OVA1 confirmed the test's high sensitivity, at 96% and negative predictive value, at 98%, substantiating clinical results reported in the previous pivotal study by Dr. Fred Ueland of U. Kentucky. This is important since doctors, payers and professional societies make their decisions, in part, on the publication of multiple independent clinical studies. The study also reported that OVA1 correctly detected 91% of early stage cancers. Combined with the result from the first study, OVA1 correctly identified 78 out of 84 early-stage ovarian malignancies among more than 1,000 patients evaluated, for a combined risk stratification sensitivity of approximately 93%.
  • Initiated a joint program with Quest Diagnostics focused in six states to improve OVA1 physician reorder rates by reestablishing OVA1 as 'top-of-mind,' as well as launched a Claims Assistance Program to assist physicians with the appeals process.
  • Published a peer-reviewed manuscript titled "A Validated Biomarker Panel To Identify Peripheral Artery Disease" in Vascular Medicine, a premier international journal featuring primary research articles and reviews on vascular disease, diagnosis, and treatment. The 1,025 patient study validated earlier biomarker discovery results in an intended use population, by identifying 85% (17 of 20) of PAD patients missed by the Framingham Risk Score's high-risk cutoff.

Q3 2012 Financial Highlights
Total revenue in the third quarter of 2012 was $319,000, comprised of $205,000 in OVA1 sales and $114,000 in license fees from Quest Diagnostics. Product revenue from OVA1 sales in the third quarter of 2012 was flat as compared to the same year-ago quarter.

Total operating expenses decreased in the third quarter to $2.6 million from $4.8 million in the same year-ago quarter. The decrease was primarily the result of lower clinical trial costs due to Vermillion's Peripheral Artery Disease (PAD) multi-marker intended use study having been completed in 2011, lower legal expenses, and continuing cost containment with improved operational efficiency. This also resulted in lower operating expenses for the nine months ended September 30, 2012, which totaled $9.0 million as compared to $15.5 million in the same year-ago period.

Net loss for the third quarter was $2.0 million or $(0.13) per share, an improvement from a loss of $4.7 million or $(0.31) per share in the same year-ago quarter. The third quarter of 2012 net loss included a $0.3 million gain for a payment received on litigation settlement. For the nine months ended September 30, 2012, net loss was $5.8 million or $(0.39) per share, as compared to $14.7 million or $(1.04) per share in the same year-ago period.

As of September 30, 2012, the company's cash and cash equivalents totaled $16.3 million as compared to $18.3 million at June 30, 2012. The company utilized $2.3 million in cash in the third quarter of 2012, offset by the $0.3 million payment received on litigation settlement during the third quarter. Management expects $2.0 million to $2.5 million in cash utilization during the fourth quarter of 2012 excluding approximately $5.9 million paid to Quest Diagnostics under the Secured Line of Credit Agreement in October 2012.

Management Commentary
"In Q3, our OVA500 pivotal study further established the valuable clinical utility of OVA1, with its high sensitivity and negative predictive value," said Gail S. Page, Vermillion's president and chief executive officer. "The manuscript of the study has recently been submitted for publication, and we plan to use the publication to aid in expanding OVA1's clinical adoption and increasing positive coverage decisions from national payers.

"Our recent loan repayment to Quest deleverages our balance sheet as well as demonstrates the success of our partnership agreement, which was designed to help bring Vermillion to this pivotal stage of its growth and development. Quest has been an important and supportive partner for many years, and we look forward to continuing our close relationship. In fact, together we successfully initiated a program focused in six states to improve OVA1 physician reorder rates by reestablishing OVA1 as 'top-of-mind.'

"Our CPT code becomes effective this January and will be priced for the first year by CMS using their gap-fill process. CMS uses the gap-fill method when no comparable molecular diagnostic exists. It determines a reimbursement amount for the first year by multiple factors, including what other payers might be paying. In anticipation of this process eventually occurring, during the early-stage of the OVA1 launch we secured reimbursement from Medicare at $516.25 per test, which is a common benchmark for reimbursement of a new diagnostic. We have also established another benchmark from the Department of Defense list price at $650.00 per test. We expect this new CPT code to streamline the claims process and strengthen our reimbursement results.

"As we wrap-up 2012 and prepare for the new year, we will work towards greater adoption by focusing on reimbursement, physician awareness and market education. Vermillion remains strongly committed to advancing the market adoption of OVA1 as the most sensitive ovarian cancer diagnostic on the market today. As we further develop our ovarian cancer franchise, we plan to expand beyond clinical labs to address the broader market, including hospitals and other points-of-care."

CEO Succession Plan
As previously announced, the company's board has formed a succession committee of independent directors to oversee the process of identifying and selecting a new CEO. It has also retained a leading executive search firm with experience in CEO transitions to advise the board on potential candidates. Gail Page will continue in her role until the new CEO is appointed, and after assisting in the transition, plans to act as a strategic advisor for the company as required by the board of directors.

Conference Call and Webcast
Vermillion will hold a conference call to discuss its third quarter financial results later today, Monday, November 12, 2012 at 4:30 p.m. Eastern time. Management will host the presentation, followed by a question and answer period.

Date: Monday, November 12, 2012
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-800-736-4610
International: 1-212-231-2900
Conference ID#: 21607929
Webcast: http://edge.media-server.com/m/p/saaeq3ma/lan/en

The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call and until November 26, 2012.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay pin number: 21607929

About OVA1
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125.(1) In addition, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment,(1) and it increased detection of malignancy over ACOG guidelines from 77% to 94%.(2) As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics.

Citings:
1)     Ueland, FR, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 2011
2)     Miller R, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 2011

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at www.vermillion.com.

Forward-Looking Statement:
Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the U.S. Securities and Exchange Commission (SEC). All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.

Investor Relations Contact:
Liolios Group
Scott Liolios or Ron Both
Tel 949-574-3860
[email protected]

 

Vermillion, Inc.

Consolidated Balance Sheets

(Amounts in Thousands, Except Share and Par Value Amounts)

(Unaudited)


 September 30,


December 31,


2012


2011

Assets




Current assets:




Cash and cash equivalents

$          16,328


$      22,477

Accounts receivable

128


99

Prepaid expenses and other current assets

263


317

Total current assets

16,719


22,893

Property and equipment, net

163


216

Other assets

-


2

Total assets

$          16,882


$      23,111





Liabilities and Stockholders' Equity




Current liabilities:




Accounts payable

$               661


$        1,331

Accrued liabilities

1,870


2,592

Short-term debt

7,000


7,000

Deferred revenue

1,076


553

Total current liabilities

10,607


11,476

Deferred revenue

883


1,224

Other liabilities

-


52

Total liabilities

11,490


12,752

Commitments and contingencies




Stockholders' equity:




Preferred stock, $0.001 par value, 5,000,000 shares authorized,

   none issued and outstanding at  September 30, 2012 and

   December 31, 2011, respectively




-


-

Common stock, $0.001 par value, 150,000,000 shares authorized

  at  September 30, 2012 and December 31, 2011; 15,095,288 and

  14,900,831 shares issued and outstanding at September 30, 2012

  and December 31, 2011, respectively




15


15

Additional paid-in capital

327,601


326,796

Accumulated deficit

(322,070)


(316,299)

Accumulated other comprehensive loss

(154)


(153)

Total stockholders' equity

5,392


10,359

Total liabilities and stockholders' equity

$          16,882


$     23,111





         

 

Vermillion, Inc.

Consolidated Statements of Operations

(Amounts in Thousands, Except Share and Per Share Amounts)

(Unaudited)



Three Months Ended

September 30,


Nine Months Ended

September 30,


2012


2011


2012


2011









Revenue:








Product

$ 205


$ 206


$ 611


$ 714

License

114


114


341


341

Total revenue

319


320


952


1,055









Cost of revenue:








Product

33


26


99


105

Total cost of revenue

33


26


99


105

Gross profit

286


294


853


950









Operating expenses:








Research and development(1)

429


1,370


1,883


4,219

Sales and marketing(2)

1,082


1,499


3,722


4,320

General and administrative(3)

1,073


1,952


3,381


6,982

Total operating expenses

2,584


4,821


8,986


15,521

Loss from operations

(2,298)


(4,527)


(8,133)


(14,571)

Interest income

7


18


23


55

Interest expense

(66)


(100)


(197)


(330)

Gain on sale of instrument business

50


-


1,830


-

Gain on litigation settlement, net

331


-


710


-

Change in fair value of warrants

-


32


-


374

Reorganization items

-


(42)


88


(74)

Other expense, net

(45)


(32)


(92)


(109)

Loss before income taxes

(2,021)


(4,651)


(5,771)


(14,655)

Income tax benefit (expense)

-


-


-


-

Net loss

$ (2,021)


$ (4,651)


$ (5,771)


$ (14,655)

Net loss per share - basic and diluted

$   (0.13)


$   (0.31)


$   (0.39)


$     (1.04)

Comprehensive loss

$ (2,021)


$ (4,650)


$ (5,772)


$ (14,652)









Weighted average common shares used to compute basic and diluted net loss per common share

15,057,027


14,820,694


14,972,877


14,041,549









Non-cash stock-based compensation expense included in operating expenses:





(1) Research and development

$ 25


$ 181


$ 99


$ 590

(2) Sales and marketing

55


40


148


122

(3) General and administrative

168


211


552


2,264

 

SOURCE Vermillion, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
Because IoT devices are deployed in mission-critical environments more than ever before, it’s increasingly imperative they be truly smart. IoT sensors simply stockpiling data isn’t useful. IoT must be artificially and naturally intelligent in order to provide more value In his session at @ThingsExpo, John Crupi, Vice President and Engineering System Architect at Greenwave Systems, will discuss how IoT artificial intelligence (AI) can be carried out via edge analytics and machine learning techn...
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
In the enterprise today, connected IoT devices are everywhere – both inside and outside corporate environments. The need to identify, manage, control and secure a quickly growing web of connections and outside devices is making the already challenging task of security even more important, and onerous. In his session at @ThingsExpo, Rich Boyer, CISO and Chief Architect for Security at NTT i3, discussed new ways of thinking and the approaches needed to address the emerging challenges of security i...
SYS-CON Events announced today that GrapeUp, the leading provider of rapid product development at the speed of business, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market acr...
From 2013, NTT Communications has been providing cPaaS service, SkyWay. Its customer’s expectations for leveraging WebRTC technology are not only typical real-time communication use cases such as Web conference, remote education, but also IoT use cases such as remote camera monitoring, smart-glass, and robotic. Because of this, NTT Communications has numerous IoT business use-cases that its customers are developing on top of PaaS. WebRTC will lead IoT businesses to be more innovative and address...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, discussed the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insights from the vast t...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
Recently, IoT seems emerging as a solution vehicle for data analytics on real-world scenarios from setting a room temperature setting to predicting a component failure of an aircraft. Compared with developing an application or deploying a cloud service, is an IoT solution unique? If so, how? How does a typical IoT solution architecture consist? And what are the essential components and how are they relevant to each other? How does the security play out? What are the best practices in formulating...
In his session at @ThingsExpo, Arvind Radhakrishnen discussed how IoT offers new business models in banking and financial services organizations with the capability to revolutionize products, payments, channels, business processes and asset management built on strong architectural foundation. The following topics were covered: How IoT stands to impact various business parameters including customer experience, cost and risk management within BFS organizations.
SYS-CON Events announced today that Elastifile will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Elastifile Cloud File System (ECFS) is software-defined data infrastructure designed for seamless and efficient management of dynamic workloads across heterogeneous environments. Elastifile provides the architecture needed to optimize your hybrid cloud environment, by facilitating efficient...
SYS-CON Events announced today that Golden Gate University will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Since 1901, non-profit Golden Gate University (GGU) has been helping adults achieve their professional goals by providing high quality, practice-based undergraduate and graduate educational programs in law, taxation, business and related professions. Many of its courses are taug...
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
An increasing number of companies are creating products that combine data with analytical capabilities. Running interactive queries on Big Data requires complex architectures to store and query data effectively, typically involving data streams, an choosing efficient file format/database and multiple independent systems that are tied together through custom-engineered pipelines. In his session at @BigDataExpo at @ThingsExpo, Tomer Levi, a senior software engineer at Intel’s Advanced Analytics ...